Acquired

Carmot Therapeutics Stock

Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.

Sign up today and learn more about Carmot Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Carmot Therapeutics Stock

Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases. They employ their patented technology, chemotype evolution, to address the fundamental causes of disease and speed the discovery of disease-modifying therapies.

Funding History

April 2010$1.5M
July 2012$500K
August 2017$10.8M
January 2018$15.0M
September 2020$47.0M
July 2022$160M
July 2022$160M
May 2023$150M

Management

Founder & CEO

Stig K. Hansen

Board Member

Tim Garnett

Board Member

Peter Svennilson

Board Director

Aetna Wun Trombley

Chief Business Officer

James D. Watson

Chief Financial and Chief Operating Offer

Michael Gray

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo